Comparative Pharmacology
Head-to-head clinical analysis: IODOHIPPURATE SODIUM I 131 versus SODIUM PHOSPHATE P 32.
Head-to-head clinical analysis: IODOHIPPURATE SODIUM I 131 versus SODIUM PHOSPHATE P 32.
IODOHIPPURATE SODIUM I 131 vs SODIUM PHOSPHATE P 32
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodohippurate sodium I 131 is a radioactive diagnostic agent that is actively transported by the renal tubules, allowing imaging of renal morphology and function. The iodine-131 emits gamma radiation, enabling scintigraphic evaluation of renal blood flow, tubular secretion, and excretion.
Sodium phosphate P 32 is a radioactive isotope that emits beta particles, causing ionization and subsequent cell death, particularly in rapidly dividing cells. It is incorporated into DNA and RNA, concentrating in tissues with high metabolic activity such as bone marrow and neoplastic cells.
Adult: 5-30 microcuries (0.185-1.11 MBq) intravenously for renal function studies.
Intravenous administration: 1.5 mCi (55.5 MBq) per 70 kg body weight, single dose. For polycythemia vera, oral dose: 3-5 mCi (111-185 MBq) as a single dose. Frequency is one-time or as needed based on response.
None Documented
None Documented
Terminal elimination half-life is approximately 60 minutes in patients with normal renal function. In renal impairment, half-life may be prolonged up to several hours, correlating with reduced clearance.
Terminal elimination half-life: 14.3 days (range 13-16 days). Clinically relevant for bone marrow suppression monitoring; cumulative effect over multiple doses.
Primarily renal; >90% of administered dose excreted unchanged in urine within 24 hours via glomerular filtration and tubular secretion. Fecal excretion <2%.
Renal: ~40% within 24 hours via glomerular filtration; Fecal: ~60% over 1-2 weeks as unabsorbed or secreted into bile. Total elimination approaches 100% after 2 weeks.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical